Bioage Labs Inc has a consensus price target of $42.33 based on the ratings of 3 analysts. The high is $45 issued by Citigroup on October 21, 2024. The low is $40 issued by Morgan Stanley on October 21, 2024. The 3 most-recent analyst ratings were released by Citigroup, Morgan Stanley, and Jefferies on October 21, 2024, respectively. With an average price target of $42.33 between Citigroup, Morgan Stanley, and Jefferies, there's an implied 121.18% upside for Bioage Labs Inc from these most-recent analyst ratings.
1calculated from analyst ratings
The latest price target for Bioage Labs (NASDAQ:BIOA) was reported by Citigroup on October 21, 2024. The analyst firm set a price target for $45.00 expecting BIOA to rise to within 12 months (a possible 135.11% upside). 3 analyst firms have reported ratings in the last year.
The latest analyst rating for Bioage Labs (NASDAQ:BIOA) was provided by Citigroup, and Bioage Labs initiated their buy rating.
There is no last upgrade for Bioage Labs
There is no last downgrade for Bioage Labs.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Bioage Labs, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Bioage Labs was filed on October 21, 2024 so you should expect the next rating to be made available sometime around October 21, 2025.
While ratings are subjective and will change, the latest Bioage Labs (BIOA) rating was a initiated with a price target of $0.00 to $45.00. The current price Bioage Labs (BIOA) is trading at is $19.14, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.